Theravance Biopharma, Inc.·4

Feb 24, 7:43 PM ET

Winningham Rick E 4

4 · Theravance Biopharma, Inc. · Filed Feb 24, 2026

Insider Transaction Report

Form 4
Period: 2026-02-20
Winningham Rick E
DirectorCHIEF EXECUTIVE OFFICER
Transactions
  • Tax Payment

    Ordinary Shares

    [F1]
    2026-02-20$19.66/sh74,975$1,474,0091,576,094 total
Holdings
  • Ordinary Shares

    (indirect: As Custodian)
    23,400
  • Ordinary Shares

    (indirect: By Trust)
    92,567
Footnotes (1)
  • [F1]Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
Signature
/s/ Brett A Grimaud, Attorney-in-Fact|2026-02-24

Documents

1 file
  • 4
    form4-02252026_120248.xmlPrimary